fda removes semaglutide shortage list 2025 Cheap, compounded versions of Ozempic, Wegovy may go away after decision FDA declares semaglutide (Ozempic/Wegovy) shortage

What it would do is close the bulks-list pathway for routine future use of these three drugs removing one of the last broad legal foundations for large-volume compounding outside of patient-specific or shortage scenarios

Compounded semaglutide is a medication prepared by licensed 503A compounding pharmacies to precise specifications for individual patients

Due to the financial success of semaglutide, it is no surprise that other pharmaceutical companies are trying to break into the market with the same zeal as Novo Nordisk

How the Process Works: From Assessment to Medication Delivery Understanding the step-by-step experience helps set realistic expectations

injection formulas or alternative timing may be recommended instead